Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2013

View Archived Issues

BioFire commences studies to support U.S. and E.U. approval of FilmArray GI Panel

Takeda reviews highlights of first quarter of fiscal 2013

ReNeuron awarded grant for phase II stroke trial

Siga Technologies selects candidate for dengue fever program

Actelion agrees to acquire Ceptaris Therapeutics pending Valchlor approval

PharmAthene and Theraclone Sciences sign definitive merger agreement

Kinex Pharmaceuticals obtains research support

Clinical studies reveal promise for OptiNose Breath Powered sumatriptan for migraine

P2X1 receptor revealed as a target in transfusion-related acute lung injury

Amblyomin-X has anticoagulant and oncolytic activity

Dainippon Sumitomo Pharma offers overview of first quarter of fiscal 2013

U.S. group presents novel oligonucleotides for familial dysautonomia

GW Pharmaceuticals reports data from Sativex study in MS spasticity

Isis Pharmaceuticals reports data from phase II ISIS-CRPRx study

Sanofi Pasteur launches phase III program for C. difficile vaccine

Compugen and Bayer sign agreement for antibody-based anticancer immunotherapies

PDUFA date for diabetes candidate albiglutide extended 3 months

Synergy Pharmaceuticals reaches agreement with FDA for plecanatide phase III program

Analyses detail nausea, efficacy and assembly of the sumatriptan iontophoretic transdermal system

Aradigm receives NIH grant for Pulmaquin and Lipoquin

EMA extends review of Clinuvel's SCENESSE to January 2014

Ono Pharmaceutical stops study of remimazolam in Japan; phase II study approved in Germany

The Medicines Company completes acquisition of ProFibrix following phase III results for Fibrocaps

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.